BioCentury
ARTICLE | Clinical News

JNJ-42165279: Phase II hold

February 1, 2016 8:00 AM UTC

Johnson & Johnson’s Janssen Research & Development unit voluntarily suspended dosing in a double-blind, placebo-controlled, international Phase II trial evaluating 25 mg oral JNJ-42165279 once daily f...